IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.370
NA - Nord America 5.959
AS - Asia 3.348
SA - Sud America 503
Continente sconosciuto - Info sul continente non disponibili 294
AF - Africa 55
OC - Oceania 2
Totale 16.531
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.851
RU - Federazione Russa 4.858
SG - Singapore 1.203
CN - Cina 716
VN - Vietnam 532
IE - Irlanda 487
HK - Hong Kong 436
IT - Italia 435
BR - Brasile 405
DE - Germania 160
KR - Corea 148
GB - Regno Unito 144
IN - India 107
CA - Canada 50
AR - Argentina 47
BD - Bangladesh 45
FR - Francia 43
MX - Messico 34
AT - Austria 31
JP - Giappone 29
GR - Grecia 27
UA - Ucraina 27
NL - Olanda 24
SE - Svezia 24
FI - Finlandia 23
ID - Indonesia 21
TR - Turchia 21
ES - Italia 18
BE - Belgio 16
PL - Polonia 16
CO - Colombia 14
EG - Egitto 14
IQ - Iraq 14
EC - Ecuador 11
MA - Marocco 11
PK - Pakistan 11
ZA - Sudafrica 11
JM - Giamaica 10
LT - Lituania 9
VE - Venezuela 8
CL - Cile 7
CR - Costa Rica 6
SA - Arabia Saudita 6
TH - Thailandia 6
TN - Tunisia 6
UZ - Uzbekistan 6
IR - Iran 5
KZ - Kazakistan 5
IL - Israele 4
JO - Giordania 4
NP - Nepal 4
PA - Panama 4
PH - Filippine 4
TW - Taiwan 4
UY - Uruguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
DK - Danimarca 3
KE - Kenya 3
PE - Perù 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
EU - Europa 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 16.239
Salva come PNG Salva come JPEG
Città #
Moscow 1.777
San Jose 623
Singapore 573
Dublin 476
Hong Kong 429
Santa Clara 385
Ashburn 307
Chandler 237
Ho Chi Minh City 177
Hefei 170
Seoul 144
New York 140
Hanoi 131
Los Angeles 106
Beijing 97
Dallas 88
Naples 79
The Dalles 77
Bengaluru 68
Atlanta 63
Princeton 52
Roxbury 51
Jacksonville 43
San Francisco 43
Da Nang 41
Milan 38
Bremen 34
Nuremberg 34
Orem 34
Cambridge 30
Council Bluffs 30
São Paulo 29
Phoenix 26
Denver 23
Des Moines 23
Medford 23
Brooklyn 21
Falkenstein 21
Memphis 21
Munich 20
Mexico City 19
Rome 19
Haiphong 18
Boardman 17
Brussels 16
Tokyo 15
Aversa 14
Frankfurt am Main 14
Rio de Janeiro 14
Chicago 13
Helsinki 13
Montreal 13
Toronto 13
Ann Arbor 12
Hyderabad 12
Vienna 12
Guangzhou 11
Houston 11
London 11
Turin 11
Wilmington 11
Hải Dương 10
Nanjing 10
Warsaw 10
Amsterdam 9
Thái Nguyên 9
Belo Horizonte 8
Campinas 8
Curitiba 8
Ercolano 8
Nha Trang 8
Ninh Bình 8
Seattle 8
Shenzhen 8
Sivas 8
Thái Bình 8
Boston 7
Cairo 7
Caserta 7
Dhaka 7
Florence 7
Jakarta 7
Jinan 7
Baghdad 6
Brasília 6
Can Tho 6
Columbus 6
Madrid 6
Salerno 6
San José 6
Stockholm 6
Bangkok 5
Belluno 5
Biên Hòa 5
Bologna 5
Buenos Aires 5
Buffalo 5
Bắc Ninh 5
Bến Tre 5
Chennai 5
Totale 7.343
Salva come PNG Salva come JPEG
Nome #
The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies 2.603
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 321
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 276
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 262
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 261
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 195
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 185
Advanced Heart Failure in Special Population—Pediatric Age 176
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 166
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 163
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 160
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 158
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 156
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 156
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 152
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 140
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 140
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 136
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 135
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 134
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 132
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 132
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 131
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 131
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 131
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 130
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 129
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 128
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 128
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 126
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 126
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 125
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 125
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 125
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 125
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 124
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 124
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 123
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 121
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 120
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 118
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 118
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 116
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 114
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 114
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 114
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 113
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 111
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 110
Early-onset MINOCA: Prognostic implications and considerations for practice 110
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 109
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 108
A pragmatic approach for thrombotic prevention after acute coronary syndromes 107
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 107
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 106
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 106
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 104
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 102
Coronary stent thickness: thinner is (always) better for all lesions? 102
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 101
[Long COVID: nosographic aspects and clinical epidemiology] 101
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 101
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 101
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 101
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 99
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 99
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 97
Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference 97
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 96
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 95
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 95
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 94
Artificial intelligence in cardiovascular prevention: new ways will open new doors 93
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 93
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 93
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 93
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 93
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 93
null 93
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 92
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 90
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 90
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 89
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 89
Epigenetic mechanisms underlying the beneficial effects of cardiac rehabilitation. An overview from the working groups of “cellular and molecular biology of the heart” and “cardiac rehabilitation and cardiovascular prevention” of the Italian Society of Cardiology (SIC) 88
How has COVID-19 impacted the care of patients with acute coronary syndromes? 88
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 88
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 87
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 86
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 86
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 85
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 85
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 84
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 84
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 83
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 83
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 83
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 81
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 81
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial 80
Totale 14.430
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022421 0 3 8 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20269.209 359 526 487 418 678 4.569 606 589 364 298 181 134
2026/20273.452 2.489 963 0 0 0 0 0 0 0 0 0 0
Totale 16.531